Lineage Cell narrows Q4 net loss to $3.3M; OpRegen gets FDA RMAT designation

Lineage Cell Therapeutics, Inc.

Net loss of $3.3M ($0.02/shr) for Q4 2024 vs $4.8M ($0.03/shr) in Q4 2023; revenue $2.9M vs $2.1M.
Cash of $47.8M at Dec 31, 2024 plus $5.5M from Jan 2025 close; funds operations into Q1 2027.
OpRegen (dry AMD/GA) received FDA RMAT designation; positive 24-month visual acuity data reported.
OPC1 DOSED study initiated Feb 2025 in spinal cord injury; UC San Diego Health first site.
Closed financings for $44M gross proceeds; potential $36M from milestone-linked warrants.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.